Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 207

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells

Open access
Lacher, Sebastian B., Dörr, Janina, de Almeida, Gustavo P., Hönninger, Julian, Bayerl, Felix, Hirschberger, Anna, Pedde, Anna-Marie, Meiser, Philippa, Ramsauer, Lukas, Rudolph, Thomas J., Spranger, Nadine, Morotti, Matteo, Grimm, Alizee J., Jarosch, Sebastian, Oner, Arman, Gregor, Lisa, Lesch, Stefanie, Michaelides, Stefanos, Fertig, Luisa, Briukhovetska, Daria, Majed, Lina, Stock, Sophia, Busch, Dirk H., Buchholz, Veit R., Knolle, Percy A., Zehn, Dietmar, Dangaj Laniti, Denarda, Kobold, Sebastian, Böttcher, Jan P. · 2024 · Nature

Abstract

Cancer-specific TCF1+ stem-like CD8+ T cells can drive protective anticancer immunity through expansion and effector cell differentiation 1–4; however, this response is dysfunctional in tumours. Current cancer immunotherapies 2,5–9 can promote anticancer responses through TCF1+ stem-like CD8+ T cells in some but not all patients. This variation points towards currently ill-defined mechanisms that limit TCF1+CD8+ T cell-mediated anticancer immunity. Here we demonstrate that tumour-derived prostaglandin E2 (PGE 2) restricts the proliferative expansion and effector differentiation of TCF1+CD8+ T cells within tumours, which promotes cancer immune escape. PGE 2 does not affect the priming of TCF1+CD8+ T cells in draining lymph nodes. PGE 2 acts through EP 2 and EP 4 (EP 2/EP 4) receptor signalling in CD8+ T cells to limit the intratumoural generation of early and late effector T cell populations that originate from TCF1+ tumour-infiltrating CD8+ T lymphocytes (TILs). Ablation of EP 2/EP 4 signalling in cancer-specific CD8+ T cells rescues their expansion and effector differentiation within tumours and leads to tumour elimination in multiple mouse cancer models. Mechanistically, suppression of the interleukin-2 (IL-2) signalling pathway underlies the PGE 2-mediated inhibition of TCF1+ TIL responses. Altogether, we uncover a key mechanism that restricts the IL-2 responsiveness of TCF1+ TILs and prevents anticancer T cell responses that originate from these cells. This study identifies the PGE 2–EP 2/EP 4 axis as a molecular target to restore IL-2 responsiveness in anticancer TILs to achieve cancer immune control.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-024-07254-x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 207

Metadata

Authors
Lacher, S. B., Dörr, J., de Almeida, G. P., Hönninger, J., Bayerl, F., Hirschberger, A., Pedde, A.-M., Meiser, P., Ramsauer, L., Rudolph, T. J., Spranger, N., Morotti, M., Grimm, A. J., Jarosch, S., Oner, A., Gregor, L., Lesch, S., Michaelides, S., Fertig, L., Briukhovetska, D., Majed, L., Stock, S., Busch, D. H., Buchholz, V. R., Knolle, P. A., Zehn, D., Dangaj Laniti, D., Kobold, S., & Böttcher, J. P.
Venue
Nature
Published
2024-04-24
Volume
629
Issue
8011
Pages
417-425
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4395113153
Cited by
207
References
15
FWCI
31.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. https://app.cochat.ai/papers/10.1038/s41586-024-07254-x
The paper
Lacher, S. B., Dörr, J., de Almeida, G. P., Hönninger, J., Bayerl, F., Hirschberger, A., Pedde, A.-M., Meiser, P., Ramsauer, L., Rudolph, T. J., Spranger, N., Morotti, M., Grimm, A. J., Jarosch, S., Oner, A., Gregor, L., Lesch, S., Michaelides, S., Fertig, L., . . . Böttcher, J. P. (2024). PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature. https://doi.org/10.1038/s41586-024-07254-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.